RLMD vs. CTMX, NVCT, RZLT, ABEO, IMUX, RPTX, GLYC, SCTL, CTXR, and RNAC
Should you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include CytomX Therapeutics (CTMX), Nuvectis Pharma (NVCT), Rezolute (RZLT), Abeona Therapeutics (ABEO), Immunic (IMUX), Repare Therapeutics (RPTX), GlycoMimetics (GLYC), Societal CDMO (SCTL), Citius Pharmaceuticals (CTXR), and Cartesian Therapeutics (RNAC). These companies are all part of the "pharmaceutical preparations" industry.
Relmada Therapeutics (NASDAQ:RLMD) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
Relmada Therapeutics currently has a consensus target price of $25.00, indicating a potential upside of 539.39%. CytomX Therapeutics has a consensus target price of $6.42, indicating a potential upside of 53.14%. Given Relmada Therapeutics' higher probable upside, equities research analysts clearly believe Relmada Therapeutics is more favorable than CytomX Therapeutics.
Relmada Therapeutics has a net margin of 0.00% compared to CytomX Therapeutics' net margin of -0.56%. CytomX Therapeutics' return on equity of 0.00% beat Relmada Therapeutics' return on equity.
CytomX Therapeutics received 354 more outperform votes than Relmada Therapeutics when rated by MarketBeat users. Likewise, 66.19% of users gave CytomX Therapeutics an outperform vote while only 41.03% of users gave Relmada Therapeutics an outperform vote.
Relmada Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.
45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 18.0% of Relmada Therapeutics shares are held by insiders. Comparatively, 7.0% of CytomX Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
CytomX Therapeutics has higher revenue and earnings than Relmada Therapeutics. CytomX Therapeutics is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, CytomX Therapeutics had 8 more articles in the media than Relmada Therapeutics. MarketBeat recorded 14 mentions for CytomX Therapeutics and 6 mentions for Relmada Therapeutics. CytomX Therapeutics' average media sentiment score of 0.40 beat Relmada Therapeutics' score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media.
Summary
CytomX Therapeutics beats Relmada Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Relmada Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Relmada Therapeutics Competitors List
Related Companies and Tools
